MARIANI PETER J 4

What Happened

• Peter J. Mariani, Chief Financial Officer of Cytosorbents Corporation (CTSO), made open-market purchases totaling 100,000 shares on June 15, 2026. The reported weighted-average price was $0.44 per share, for an aggregate cost of approximately $44,000. This was a purchase (acquisition) transaction.

Key Details

• Transaction date: 2026-06-15; Form 4 filed 2026-06-16 (timely filing).
• Transaction type/code: P = Purchase (open market).
• Price: weighted average $0.44; trades occurred at prices in the range $0.40–$0.45 (Reporting Person can provide per-trade breakdown on request).
• Shares acquired: 100,000; cash paid ≈ $44,000.
• Shares owned after transaction: 316,613 common shares (216,613 previously owned + 100,000 purchased), per the filing.
• Unvested/award holdings disclosed:
  • 110,000 RSUs (settle on vesting upon a Change in Control or on Aug 14, 2028, subject to service).
  • 65,000 RSUs (32,500 remain unvested; vest in two installments over two years).
  • 175,000 RSUs (settle on a Change in Control).
  • 71,500 RSUs (vest half on each of the first and second anniversaries of grant).
• No option exercises, gifts, or tax-withholding shares reported in this filing.

Context

• This was a straightforward open-market buy by the CFO. Purchases by executives are sometimes viewed by investors as a positive signal about their view of the company, but they do not prove future performance. The filing discloses both current owned shares and several unvested RSU awards that could convert to Common Stock under the conditions noted above.